Z
Zevra Therapeutics, Inc. (ZVRA)
NMS – Real vaqt narxi. Valyuta: USD
11.05
+0.25 (2.31%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
11.05
+0.25 (2.31%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Zevra Therapeutics, Inc., tijorat bosqichidagi kompaniya, Qo'shma Shtatlarda kam uchraydigan kasalliklarni davolash uchun qondirilmagan ehtiyojlarni qondirishga qaratilgan. Kompaniya o'z mahsulotlarini Ligand Activated Technology platformasi orqali ishlab chiqadi. Uning asosiy dori nomzodi KP1077 bo'lib, u KP1077IH dan iborat bo'lib, u idiopatik giperinsomniyani davolash uchun 3-bosqich klinik sinovdan o'tmoqda va KP1077N, u narkolepsiyani davolash uchun 3-bosqich klinik sinovdan o'tmoqda. Kompaniya tomir Ehlers-Danlos sindromini davolash uchun 3-bosqich klinik sinovdan o'tayotgan tadqiqot dori nomzodi Celiprololni ishlab chiqmoqda. Bundan tashqari, u olti yosh va undan katta bemorlarda diqqat etishmovchiligi va giperaktivlik buzilishini davolash uchun kuniga bir marta qabul qilinadigan AZSTARYS; siydik sikli buzilishlarini davolash uchun OLPRUVA; va ultra-nodir neyrodegenerativ kasallik bo'lgan Niemann-Pick kasalligi C turini davolash uchun MIPLYFFA ni taklif etadi. Kompaniya Commave Therapeutics SA bilan SDX va d-metilfenidatni o'z ichiga olgan kompaniyaning dori nomzodlarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha hamkorlik va litsenziya shartnomasiga ega; va OLPRUVA uchun huquqlarni ishlab chiqish va tijoratlashtirish bo'yicha Acer va Relief Therapeutics, Inc. bilan litsenziya shartnomasiga ega. Kompaniya ilgari KemPharm, Inc. nomi bilan tanilgan va 2023 yil fevral oyida Zevra Therapeutics, Inc. deb o'zgartirgan. Kompaniya 2006 yilda tashkil etilgan va shtab-kvartirasi Massachusets shtatining Boston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Adrian Quartel FFPM, M.D. | Chief Medical Officer |
| Dr. Christopher M. Lauderback Ph.D. | Senior Vice President of Manufacturing |
| Mr. Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality |
| Mr. Joshua M. Schafer M.B.A., M.S. | Chief Commercial Officer |
| Mr. Justin A. Renz CPA, MBA | CFO & Treasurer |
| Mr. Neil F. McFarlane | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | zvra-20260331.htm |
| 2026-04-20 | DEF 14A | zvra-20260416.htm |
| 2026-04-06 | PRE 14A | zvra-20260403.htm |
| 2026-03-16 | 8-K | zvra-20260312.htm |
| 2026-03-09 | 8-K | zvra-20260304.htm |
| 2026-03-09 | 10-K | zvra-20251231.htm |
| 2025-12-17 | 8-K | zvra-20251211.htm |
| 2025-12-02 | 8-K | zvra-20251126.htm |
| 2025-11-20 | 8-K | d78999d8k.htm |
| 2025-11-05 | 10-Q | zvra-20250930.htm |
| Mr. Rahsaan W. Thompson J.D. | Chief Legal Officer, Secretary & Compliance Officer |
| Ms. Alison Peters | Chief People Officer |
| Ms. Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications |
| Ms. Tanya Hayden | Senior VP & Chief of Staff |